Recent News

• 10.29.2026 - Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
• 10.19.2026 - Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
• 10.02.2026 - Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
• 09.17.2026 - Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
• 09.16.2026 - LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
• 09.03.2026 - Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
• 09.03.2026 - LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
• 09.01.2026 - Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
• 08.31.2026 - Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
• 08.24.2026 - LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease

Recent Filings

• 10.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.12.2026 - 3 Initial statement of beneficial ownership of securities
• 08.06.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.04.2026 - 144 Report of proposed sale of securities
• 08.03.2026 - 144 Report of proposed sale of securities
• 07.29.2026 - 8-K Current report
• 07.29.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.29.2026 - EX-99.1 EX-99.1